UK, n = 147 | Japan, n = 312 | p | EUVAS, n = 235 | JMAAV, n = 48 | |
---|---|---|---|---|---|
General (%) | 124 (84.4) | 234 (75.0) | 0.58 | 204 (86.8) | Not done |
Skin (%) | 36 (24.5) | 35 (11.2) | < 0.01 | 43 (18.3) | 3 (6.3) |
Eye, mucosa (%) | 22 (15.0) | 21 (6.7) | < 0.01 | 36 (14.2) | 3 (6.3) |
Eye (%) | 21 (14.3) | 15 (4.8) | < 0.01 | Not done | 3 (6.3) |
Mucosa (%) | 3 (2.0) | 9 (2.9) | 0.76 | Not done | 0 |
ENT (%) | 20 (13.6) | 38 (12.2) | 0.64 | 46 (19.6) | 1 (2.1) |
Heart (%) | 6 (4.1) | 9 (2.9) | 0.57 | 14 (6.0) | 1 (2.1) |
Nerve (%) | 29 (19.7) | 92 (29.5) | 0.02 | 35 (14.9) | 24 (50.0) |
Peripheral (%) | 24 (16.3) | 82 (26.3) | 0.02 | Not done | 22 (45.8) |
Central (%) | 7 (4.8) | 16 (5.1) | 0.87 | Not done | 2 (4.2) |
Intestine (%) | 4 (2.7) | 13 (4.2) | 0.45 | 13 (5.5) | 1 (2.1) |
Kidney (%) | 121 (82.3) | 271 (86.9) | 0.19 | 231 (98.3) | 36 (75.0) |
Respiratory (%) | 51 (34.7) | 157 (52.5) | < 0.01 | 102 (43.4) | 25 (52.1) |
IP/fibrosis (%) | 25 (17.0) | 116 (37.1) | < 0.01 | Not done | 22 (45.8) |
AH (%) | 30 (20.4) | 33 (10.6) | < 0.01 | Not done | 2 (4.2) |
Others | 3 (2.0) | 1 (0.3) | Not done | 0 |
In the EUVAS database, 19 patients had only BVAS scores and without information about each organ involvement. “Others” in Cambridge included 2 aortitis and 1 vasculitis of testis. “Others” in Japan was aortitis. P value was calculated using the chi-square test comparing UK and Japan. In those analyses where the expected frequency was < 5 in 1 or more cells, the p value was calculated by Fisher’s exact test. EUVAS: European Vasculitis Society; JMAAV: Japanese patients from the MPO-ANCA-associated vasculitis trial; ENT: ear, nose, and throat; IP/fibrosis: interstitial pneumonitis/pulmonary fibrosis; AH: alveolar hemorrhage; MPO: myeloperoxidase; ANCA: antineutrophil cytoplasmic antibody; BVAS: Birmingham Vasculitis Activity Score.